IA
MRTX

IFP Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

IFP Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19
Closed -$1.11K – 3384
2024
Q1 		$1.11K Sell
19
-3,659
-99% -$216K ﹤0.01% 2844
2023
Q4 		$216K Hold
3,678
– – 0.01% 914
2023
Q3 		$160K Buy
3,678
+1,323
+56% +$47.2K 0.01% 1055
2023
Q2 		$85.1K Sell
2,355
-144
-6% -$5.93K ﹤0.01% 1390
2023
Q1 		$106K Buy
2,499
+96
+4% +$4.32K ﹤0.01% 1232
2022
Q4 		$104K Buy
2,403
+257
+12% +$16.6K ﹤0.01% 1723
2022
Q3 		$92K Buy
2,146
+145
+7% +$10.7K ﹤0.01% 1918
2022
Q2 		$86K Hold
2,001
– – ﹤0.01% 1799
2022
Q1 		$86K Buy
+2,001
New +$205K ﹤0.01% 1799
2018
Q3 		– Sell
-16,536
Closed -$815K – 4056
2018
Q2 		$815K Buy
+16,536
New +$625K 0.03% 475

IFP Advisors's MRTX Position: Q2 2024 in Review

IFP Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2024, closing a stake of 19 shares — an estimated $1.11K sold.

IFP Advisors first reported a position in MRTX in Q2 2018 and held it in 10 quarters. The position peaked at $815K in Q2 2018. 0 funds tracked by Wall St. Rank hold MRTX as of Q2 2024.

  • IFP Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • IFP Advisors sold 19 Mirati Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $1.11K.
  • IFP Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 10 quarters.
  • IFP Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $815K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2024.

Based on IFP Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.